Moore stepping down as Stem Cell Therapeutics CEO

> Stem Cell Therapeutics has reported, as per a previous press release dated June 25, 2010, the consulting agreements with Alan Moore (president & CEO) and Allen Davidoff (VP of product development) will expire on December 31, 2010. Davidoff has accepted an offer from the board and will become the company's chief scientific officer. SCT Release

> Swedish Orphan Biovitrum has announced that CEO Martin Nicklasson will leave the company. Swedish Orphan Biovitrum release

> Kevin McLaughlin has joined Acceleron Pharma as senior VP and CFO. Acceleron release

> Aushon BioSystems has named Sven Beushausen as CSO. Aushon release

> Bausch + Lomb has named Charl van Zyl as corporate VP and commercial leader, Europe, Middle East and Africa (EMEA). Bausch + Lomb release

> Knopp Biosciences has announced Suresh Khemani has joined the company as VP of Commercial and Clinical Affairs. Knopp release

> Covance has promoted Rick Cimino to executive VP and group president, Clinical Development; Deborah Tanner to executive VP and group president, R&D Laboratories; and John Watson to corporate senior VP, president, Strategic Partnering, and chief commercial officer. In addition, Jon Koch was promoted to corporate VP and president, Central Laboratory Services and Lisa Uthgenannt joined Covance as corporate VP of Human Resources. Covance release

> MolMed has appointed of Germano Carganico as general manager. MolMed release

> Polish biotechnology company Selvita has named Piotr Prelich to the position of VP of sales and marketing. Selvita release

> Seattle Genetics has appointed Chris Boerner as VP, Marketing and Darren Cline as VP, Managed Markets. These appointments reflect the company's continuing preparations for the planned commercialization of brentuximab vedotin (SGN-35). Seattle Genetics expects to submit a BLA to the FDA for brentuximab vedotin in the first half of 2011. Seattle Genetics release

> NeurogesX's board of directors has voted to expand the size of the company's board from six to seven members with the appointment of Steven Nelson. NeurogesX release

> BTG plc has appointed Melanie Lee as a non-executive director of the board. BTG release

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.